

HOUSE COMMITTEE AMENDMENTS

2025 Regular Session

Amendments proposed by House Committee on Insurance to Original House Bill No. 622
by Representative Hilferty

AMENDMENT NO. 1

On page 1, line 2, delete "R.S. 22:1077.4," and insert "R.S. 22:1077.4 and R.S. 40:1081.13,"

AMENDMENT NO. 2

On page 1, line 4, after "cancer;" delete the remainder of the line and insert "to provide for application to Medicaid coverage; to provide for definitions; to provide for applicability relative to coverage plans; to provide for effectiveness; and to provide for related matters."

AMENDMENT NO. 3

On page 1, delete lines 11 through 13 in their entirety and insert in lieu thereof the following:

"of primary and metastatic tumors in the liver if the person presents with any of the following conditions:

(1) Residual disease after first-line treatment of chemotherapy.

(2) Metastatic colorectal cancer with liver-dominant or liver-only metastatic disease where a physician has determined surgery is not a good option for the patient.

(3) Tumors up to four centimeters or larger if the tumor can be treated in its entirety.

(4) Metastatic neuroendocrine tumors with systemic symptoms associated with elevated hormone levels.

B. Coverage provided pursuant to this Section may be subject to annual deductibles, coinsurance, and copayments consistent with those established under the health coverage plan."

AMENDMENT NO. 4

On page 1, line 14, change "B." to "C."

AMENDMENT NO. 5

On page 1, after line 16, insert the following:

"Section 2. R.S. 40:1081.13 is hereby enacted to read as follows:

§1081.13. Medicaid coverage; histotripsy procedures

A. The Louisiana Department of Health shall make available to persons who are eligible for Medicaid benefits under Title XIX of the Social Security Act, 42 U.S.C. 1396 et seq., coverage for histotripsy procedures for the treatment of primary and metastatic tumors in the liver if the person presents with any of the following conditions:

(1) Residual disease after first-line treatment of chemotherapy.

(2) Metastatic colorectal cancer with liver-dominant or liver-only metastatic disease where a physician has determined surgery is not a good option for the patient.

(3) Tumors up to four centimeters or larger if the tumor can be treated in its entirety.

(4) Metastatic neuroendocrine tumors with systemic symptoms associated with elevated hormone levels.

1 B. A health maintenance organization, health insurance organization, or
2 managed care organization that contracts with the state to provide or coordinate
3 healthcare services to any person eligible for Medicaid coverage pursuant to this
4 Section shall also provide certain documents to the department that address treatment
5 for rare and less common cancers through consultation with subspecialists within
6 respective fields.

7 C. Coverage provided pursuant to this Section may be subject to
8 copayments, deductibles, or other cost-sharing mechanisms.

9 D. For the purposes of this Section, "histotripsy" means a non-invasive
10 procedure that uses high-intensity sound waves to selectively destroy cancer tissue
11 in the liver.

12 Section 3. The provisions of this Act apply to any new policy, contract, or health
13 coverage plan issued on and after January 1, 2026. Any policy, contract, or health coverage
14 plan in effect prior to January 1, 2026, shall convert to conform to the provisions of this Act
15 on or before the renewal date, but no later than January 1, 2027."